Synthetic Biologics to Report Year End 2014 Financial Results

— Conference Call Scheduled for Monday, March 16, 2015, at 8:30 a.m. EDT —

ROCKVILLE, Md., March 9, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.

Synthetic Biologics, Inc. Logo

During the call, Jeffrey Riley, Synthetic Biologics’ Chief Executive Officer, will provide an update on the Company’s C. difficile prevention, constipation-predominant irritable bowel syndrome (C-IBS), Pertussis (whooping cough) and multiple sclerosis (MS) programs. C. Evan Ballantyne, Synthetic Biologics’ Chief Financial Officer, will review the Company’s financial results for the year ended December 31, 2014.

Interested parties should call 1-888-347-5280 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=101639. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=101639, for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

Logo – https://photos.prnewswire.com/prnh/20130522/MM19465LOGO 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-year-end-2014-financial-results-300046866.html

SOURCE Synthetic Biologics, Inc.